Unplanned admission to hospital · patients with neuromuscular and chest wall disorders and chronic hypoventilation
It is very uncertain whether nocturnal ventilation changes unplanned admission to hospital compared with no ventilation (very low certainty).
1 finding from 1 review
No improvement of hypoventilation symptoms: long‐term · patients with neuromuscular and chest wall disorders and chronic hypoventilation
It is very uncertain whether nocturnal ventilation changes no improvement of hypoventilation symptoms: long‐term compared with no ventilation (very low certainty).
1 finding from 1 review
No improvement of daytime hypercapnia: long‐term · patients with neuromuscular and chest wall disorders and chronic hypoventilation
It is very uncertain whether nocturnal ventilation changes no improvement of daytime hypercapnia: long‐term compared with no ventilation (very low certainty).
1 finding from 1 review
Mortality at 1 year (or more) Not measured ‐ data reported for mortality at 3 months · patients with neuromuscular and chest wall disorders and chronic hypoventilation
It is very uncertain whether volume‐cycled ventilation changes mortality at 1 year (or more) Not measured ‐ data reported for… compared with pressure‐cycled ventilation (very low certainty).
1 finding from 1 review
Unplanned admission to hospital · patients with neuromuscular and chest wall disorders and chronic hypoventilation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No improvement of hypoventilation symptoms: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No improvement of daytime hypercapnia: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · patients with Guillain‐Barré syndrome
1 finding from 1 review
Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).
1 finding from 1 review
Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).
1 finding from 1 review
Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).
1 finding from 1 review
Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome
IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).
1 finding from 1 review
Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Intensive insulin therapy may leads to lower occurrence of CIP/CIM ‐ in total population randomised compared with conventional insulin therapy (low certainty).
1 finding from 1 review
Death ‐ at 180 days after ICU admission, in total population randomised · critically ill patients
Corticosteroids showed no clear difference in death ‐ death at 180 days in total population randomised compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ shock · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ shock compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ serious infection · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ serious infection compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Early physical therapy showed no clear difference in occurrence of CIP/CIM ‐ in the total population randomised compared with control (low certainty).
1 finding from 1 review